Synaptogenesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The symbolism carried over to Roman culture, which held the laurel as a symbol of victory. It was also associated with immortality, with ritual purification, prosperity and health. It is also the source of the words baccalaureate and poet laureate, as well as the expressions "assume the laurel" and "resting on one's laurels". Pliny the Elder stated that the laurel was not permitted for "profane" uses – lighting it on fire at altars "for the propitiation of divinities" was strictly forbidden, because "it is very evident that the laurel protests against such usage by crackling as it does in the fire, thus, in a manner, giving expression to its abhorrence of such treatment". Laurel was closely associated with the Roman Emperors, beginning with Augustus. Two Laurel trees flanked the entrance to Augustus' house on the Palatine Hill in Rome, which itself was connected to the Temple of Apollo Palatinus, which Augustus had built. Thus, the laurels had the dual purpose of advertising Augustus' victory in the Civil Wars and his close association with Apollo. Suetonius relates the story of Augustus' wife, and Rome's first Empress, Livia, who planted a sprig of laurel on the grounds of her villa at Prima Porta after an eagle dropped a hen with the sprig clutched in its beak onto her lap. The sprig grew into a full-size tree which fostered an entire grove of laurel trees, which were in turn added to by subsequent Emperors when they celebrated a triumph. The emperors in the Julio-Claudian dynasty all sourced their Laurel wreaths from the original tree planted by Livia.
Many such scenarios have been depicted in popular culture, such as in the 1959 film On the Beach, the 1962 novel Fail-Safe, the 1964 film Dr. Strangelove or: How I Learned to Stop Worrying and Love the Bomb, the 1983 film WarGames, and the 1984 film Threads.
Smith developed a way to color code the basic nucleotide units of DNA with fluorescent tags, green for adenine (A), yellow-green for guanine (G), orange for cytosine (C) and red for thymine (T). Four differently colored fluorophores, each one specific to a reaction with one of the bases, are covalently attached to the oligonucleotide primer for the enzymatic DNA sequence analysis. During the analysis, fragments are passed downwards through a gel tube, the smallest and lightest fragments passing through the gel tube first. A laser light passed through a filter wheel causes the bases to fluoresce. The resulting fluorescent colors are detected by a photomultiplier and recorded by a computer. The first DNA fragment to be sequenced was a common cloning vector, M13. The DNA sequencer was a critical technology for the Human Genome Project. Hood was involved with the Human Genome Project from its first meeting, held at the University of California, Santa Cruz, in 1985. Hood became an enthusiastic advocate for The Human Genome Project and its potential. Hood directed the Human Genome Center's sequencing of portions of human chromosomes 14 and 15. At the University of Washington in the 1990s, Hood, Alan Blanchard, and others developed ink-jet DNA synthesis technology for creating DNA microarrays. By 2004, their ink-jet DNA synthesizer supported high-throughput identification and quantification of nucleic acids through the creation of one of the first DNA array chips, with expression levels numbering tens of thousands of genes.
Steroid hormone receptors and related receptors are generally soluble proteins that function through gene activation. Lipid-soluble hormones target specific sequences of DNA by diffusing into the cell. When they have diffused into the cell, they bind to receptors (intracellular), and migrate into the nucleus. Their response elements are DNA sequences (promoters) that are bound by the complex of the steroid bound to its receptor. The receptors themselves are zinc-finger proteins. These receptors include those for glucocorticoids (glucocorticoid receptors), estrogens (estrogen receptors), androgens (androgen receptors), thyroid hormone (T3) (thyroid hormone receptors), calcitriol (the active form of vitamin D) (calcitriol receptors), and the retinoids (vitamin A) (retinoid receptors). Receptor-protein interactions induce the uptake and destruction of their respective hormones in order to regulate their concentration in the body. This is especially important for steroid hormones because many body systems are entirely steroid dependent.
Sources: en.wikipedia.org
Breast augmentation with fat-grafts (adipocyte tissue) harvested from the body of the patient (autologous fat) is indicated for women requiring breast reconstruction, the surgical correction of a congenital defect, and the æsthetic enhancement of the bust.
=== Gene therapy === Gene therapy was first trialled in 2014 on a single patient, and followed by clinical trials in which several patients were successfully treated. In 2023, both exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) were approved for the treatment of sickle cell disease. Kendric Cromer in October 2024 became the first commercial case in the US to receive gene therapy and was discharged from Children's National Hospital. The one-off gene-editing therapy, Casgevy, also known as Exa-cel, is to be offered to patients on the National Health Service (NHS) in England as from 2025. Both Casgevy and Lyfgenia work by first harvesting the patient's HSCs, then using CRISPR gene editing to modify their DNA in the laboratory. In parallel, the person with sickle cell disease's bone marrow undergoes a myeloablation procedure to destroy the remaining HSCs. The treated cells are then infused back into the patient, where they colonise the bone marrow and eventually resume production of blood cells. Casgevy works by editing the BCL11A gene, which normally inhibits haemoglobin F (foetal haemoglobin) production in adults. The edit increases HbF production, which is not prone to sickling. Lyfgenia introduces a new gene for T87Q-globin, which coexists with the sickling beta-globin but reduces the incidence of sickling. A study published in the New England Journal of Medicine in April 2026 showed a new CRISPR gene therapy labeled renizgamglogene autogedtemcel (abbreviated to reni-cel) that increased total hemoglobin from 9.8 to 13.8g/dL.
Rosett (1953), dean of the University of Chicago Booth School of Business, Arts and Sciences at Washington University in St. Louis, and chairman of National Bureau of Economic Research Robert L. Friedheim (1955), former director of the USC School of International Relations Calvin B. T. Lee (1955), former chancellor of University of Maryland, Baltimore County and acting president of Boston University Robert E. Paaswell (1956), civil engineer, former interim president of City College of New York and CEO of Chicago Transit Authority Kenneth Gros Louis (1959), chancellor of Indiana University system Richard A. Merrill (1959), 7th dean of the University of Virginia School of Law Stephen Joel Trachtenberg (1959), president of the University of Hartford and of George Washington University David C. Levy (1960), dean of the Parsons School of Design and president of the Corcoran Gallery of Art Steven M. Cahn (1966), provost and acting president of Graduate Center of the City University of New York Dimitri B. Papadimitriou (1970), executive vice president and provost of Bard College David Rubin (1970), professor of communications and dean of S. I. Newhouse School of Public Communications Alan Cooper (1971), provost of Jewish Theological Seminary of America, former member of Sha Na Na William Germano (1972), dean of the faculty of humanities and social sciences at Cooper Union, former editor-in-chief of Columbia University Press Saul Levmore (1973), commercial law scholar, former dean of the University of Chicago Law School Ronald Mason Jr.
== Cultural analogues == Akira Kurosawa's 1948 film Drunken Angel centers upon the efforts of Doctor Sanada, himself an alcoholic, to sustain a young gangster against tuberculosis, counseling him to abandon his self-destructive lifestyle. The character Dr. House, from the television series of the same name, can be considered as an example of this archetype in modern pop culture; his physical and emotional scars are both a burden and a driving force in his need to fix the problems of others while destroying himself. In East Coker, T. S. Eliot wrote "The wounded surgeon plies the steel/That questions the distempered part".
== Availability == Many medications are available as depot injections, including many typical and atypical antipsychotics, as well as some hormonal medications and medication for opioid use disorder. Depot injections of antipsychotics are used to improve historically low adherence in patients with diseases such as schizophrenia. Different products may be administered or implanted either by a doctor or nurse, while some are designed to be administered by the patient themselves. Self-administered depot injections are used to increase healthcare access and decrease the need to visit the doctor as frequently, especially in low and middle income countries. Insulin may also be considered a depot injection depending on formulation. Insulin glargine, for example, is designed to precipitate after injection so it can be slowly absorbed by the body over a longer period than regular insulin would be. Depot injections of insulins have been studied to better replicate the body's natural basal rate of insulin production, and which can be activated by light to control the release of insulin from the injected depot.
Sources: en.wikipedia.org
Ketogenic diet The ketogenic or "keto" diet involves intake of less than 50 g of carbohydrates daily along with increased fat and protein amounts. One type of ketogenic or low carbohydrate diet is the "Atkins" Diet, which does not restrict protein and fat amounts. Other ketogenic diets restrict the total amount of daily proteins and fats.
John Scott Award, created in 1816 as the John Scott Legacy Medal and Premium, is presented to people whose inventions are deemed to have improved the "comfort, welfare, and happiness of human kind" in a significant way. Since 1919 the Board of Directors of City Trusts of Philadelphia provide this award, recommended by an advisory committee.
Harrison (1912–1998), American chemist who studied the structure of organic compounds and their interaction with light, first woman President of the American Chemical Society Odd Hassel (1897–1981), Norwegian chemist who established the three-dimensionality of molecular geometry, 1969 Nobel Prize in chemistry Charles Hatchett (1765–1847), English chemist who discovered niobium Herbert A. Hauptman (1917–2011), American mathematician who developed a method that opened a new era in research in determination of molecular structures of crystallized materials, 1985 Nobel Prize in chemistry Walter Hawkins (1911–1992), American chemist, a pioneer of polymer chemistry, who co-invented a polymer with antioxidants that prevented deterioration even in extreme temperatures Walter Haworth (1883–1950), British chemist, 1937 Nobel Prize in chemistry "for his investigations on carbohydrates and vitamin C" Sam Hay (PhD 2004), New Zealand chemist known for in silico enzymology, quantum mechanics roles in biological processes Alma Levant Hayden (1927–1967), American spectrophotometrist known for showing that Krebiozen was a quack anti-cancer agent Jabir Ibn Hayyan (722–804), Persian-Arab chemist and alchemist, purported author of many works in Arabic
=== TV documentaries === ARTE (French/German TV Channel): Since 2018, ARTE has aired documentaries on the world of fascia, featuring Robert Schleip. SWR (German TV Channel): Documentaries aired on October 25, 2021, and September 10, 2020, explored the "fascia boom" and included contributions from Schleip.
In general, action potentials that reach the synaptic knobs cause a neurotransmitter to be released into the synaptic cleft. Neurotransmitters are small molecules that may open ion channels in the postsynaptic cell; most axons have the same neurotransmitter at all of their termini. The arrival of the action potential opens voltage-sensitive calcium channels in the presynaptic membrane; the influx of calcium causes vesicles filled with neurotransmitter to migrate to the cell's surface and release their contents into the synaptic cleft. This complex process is inhibited by the neurotoxins tetanospasmin and botulinum toxin, which are responsible for tetanus and botulism, respectively.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.